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Background. Prospectively and systematically collected data on frequency and spectrum of unexpected
clinical manifestations during primary human immunodeﬁciency virus (HIV) infection (PHI) have not been
published.
Methods. We prospectively enrolled 290 patients with documented PHI in the Zurich Primary HIV Infection
Study. Typical acute retroviral syndrome (ARS) was deﬁned as fever plus at least 1 symptom or sign typically con-
sidered to be associated with ARS; in absence of fever, presence of 2 or more ARS symptoms or signs. Atypical ARS
was deﬁned as lack of symptoms or signs, a single symptom or sign only and absence of fever, presence of symptoms
or signs that are not considered typically associated with ARS, or occurrence of an opportunistic disease. Time to
diagnosis was calculated based on estimated date of infection and ﬁrst positive HIV test.
Results. We analyzed 290 patients (271 males). PHI manifested with typical ARS in 202 (70%) and with atypical
ARS in 88 (30%) patients. Patients with atypical ARS were hospitalized 4 times more often compared with typical
ARS (43% vs 11%; P < .001). The gastrointestinal tract was the most frequent organ system affected in patients with
atypical manifestations. Only in 112 (38%) patients was HIV infection suspected during the ﬁrst medical attendance.
Patients with typical ARS were diagnosed slightly earlier compared with atypical ARS, but this difference was not
signiﬁcant (P = .3).
Conclusions. Unexpected clinical presentations occurred in a large fraction of patients with PHI and were as-
sociated with substantial morbidity. Universal HIV testing may be mandatory in high-risk groups.
Keywords. primary HIV-1 infection; acute HIV-infection; acute retroviral syndrome; ARS; atypical clinical
presentation.
Primary human immunodeﬁciency virus type 1 (HIV-
1) infection (PHI) encompasses the ﬁrst 3 to 6 months
after infection and presents symptomatically in 23%
to 92% of newly infected individuals [1–13]. Signs
and symptoms that occur during seroconversion are
often referred to as acute retroviral syndrome (ARS).
However, there is no distinct deﬁnition of ARS, and di-
verse numbers on frequency and a variety of clinical
manifestations are reported [11]. Reliable data on the
proportion of asymptomatic or oligosymptomatic PHI
are lacking since asymptomatic persons usually do not
seek medical care. Studies that include an HIV-negative
control group may be limited due to a recall bias [5, 10].
The nonspeciﬁc and transient nature of symptoms asso-
ciated with PHI provides a major diagnostic challenge
and substantially contributes to ongoing virus transmis-
sions [14]. Early recognition of PHI is therefore impor-
tant in order to interrupt the transmission chain and
maximize the potential beneﬁt of early antiretroviral
treatment (ART) [15]. Severe clinical manifestations,
including opportunistic diseases, and a broad spectrum
of affected organ systems during PHI have been report-
ed (Supplementary Appendix 1). Nevertheless, whether
the proportion and the disease pattern of atypical clin-
ical presentation during PHI inﬂuence the time to diag-
nosis has not yet systematically been studied.
We prospectively observed 290 patients with a docu-
mented PHI with regard to the infection’s clinical
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presentation. Our aim was to characterize the clinical manifes-
tations of PHI and compare them to those described in the lit-
erature, determine the proportion of patients who present with
typical or atypical ARS, and determine whether atypical presen-
tation delays diagnosis.
METHODS
Study Design and Deﬁnition of Primary HIV-1 Infection
A total of 290 patients with documented PHI were prospectively
enrolled between January 2002 and January 2013 into the
Zurich Primary HIV Infection Study, which is an open-label,
nonrandomized, observational, single-center study (http://
clinicaltrials.gov, ID 5 NCT00537966) [16]. The ethics commit-
tee of the Canton of Zurich approved the study protocol, and
written informed consent was obtained from all patients.
Acute or recent PHI was conﬁrmed in all patients as previ-
ously described [16–18]. Acute HIV infection was deﬁned as
ARS and negative or indeterminateWestern blot in the presence
of a positive p24-antigen and/or detectable HIV-1 RNA or as a
documented seroconversion with or without symptoms during
the past 90 days. Recent infection was deﬁned as possible ARS,
positive Western blot and detectable HIV-RNA, and a negative
HIV-gp120 avidity or detuned assay or as a documented acute
HIV-1 infection but with referral to our center between 90 and
180 days after the estimated date of infection (EDI).
Assessment of Acute Retroviral Syndrome
At the ﬁrst visit, a detailed history and physical examination
were performed and standard laboratory parameters were ob-
tained. Additionally, information on occurrence of an acute ill-
ness, a need for invasive procedures, and microbiological
ﬁndings during PHI were assessed. Patients were actively
screened for other sexually transmitted infections (STIs). If pa-
tients were referred from an external physician, data from the
ﬁrst external visit were recorded.
Table 1. Comparison of Typical Clinical Manifestations of Acute Retroviral Syndrome: Data From Present Study and Data From Published
Studies With Different Study Designs
Clinical Manifestation and
Laboratory Finding
Present
Study, n (%),
N = 202
Median Frequency (%) in Published Studiesa
% Range of
All Studies
Retrospective,b
n = 227
Prospective,c
n = 255
Human Immunodeficiency
Virus-Negative,d n = 8345
Clinical manifestation
Fever 178 88 78 48 88 23–100
Malaise/Fatigue 122 60 64 25 65 12–92
Pharyngitis 103 51 48 21 51 2–95
Rash 94 47 38 12 47 4–75
Lymphadenopathy 91 45 36 36 45 7–75
Weight loss 79 39 21 21 39 2–70
Headache 74 37 44 34 37 18–57
Diarrhea 71 35 32 17 35 14–48
Night sweats 68 34 14 9 34 3–48
Myalgia 56 28 46 20 28 14–92
Nausea 53 26 32 19 26 6–67
Arthralgia 44 22 27 21 22 14–92
Cough 33 16 25 14 16 4–45
Vomiting 24 12 32 11 12 3–67
Oral ulcers 24 12 17 9 12 9–30
Neurological symptoms 22 11 12 . . . 11 0–24
Genital ulcers 7 3 3 3 3 3–10
Elevated liver enzymes 124 61 21 . . . . . . 21–61
Thrombocytopenia 74 37 60 . . . . . . 37–60
A total of 202 of 290 patients presented with typical acute retroviral syndrome.
a References [1–13].
b Data from 11 retrospective studies or review articles, as summarized in Supplementary Appendix Table 2.
c Data from 5 prospective seroconverter studies with a human immunodeficiency virus (HIV)-negative control group, as shown in Supplementary Appendix Table 3.
d Data from 5 prospective studies reporting symptoms from an HIV-negative control group, as shown in Supplementary Appendix Table 4.
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Estimated Date of Infection and Time to Diagnosis
For each patient, an EDI was determined by taking into account
the different patterns of assay reactivities (ﬁrst positive and last
negative HIV test; negative, indeterminate, and positive West-
ern blot; positive p24 antigen), patient’s report of unambiguous
risk contacts, and timing of onset of ARS symptoms. The de-
tailed algorithm to calculate the EDI was previously published
[16–18]. The time to diagnosis was calculated based on the EDI
and the date of the ﬁrst positive HIV screening test.
Deﬁnition of Typical and Atypical Acute Retroviral Syndrome
First, we extensively reviewed the literature on reported signs
and symptoms associated with PHI (Supplementary Appendi-
ces 2–4) [1–6, 8–13]. Based on this literature search, we deﬁned
17 symptoms and signs that we considered typical of ARS
(Table 1). Next, we distinguished typical and atypical ARS
among our study population. ARS was considered typical in
case of documented or reported fever (temperature ≥38°C)
plus at least 1 of the symptoms or signs listed in Table 1; in
the absence of fever, 2 or more of these symptoms or signs
needed to be present. ARS was deﬁned as atypical in cases of
lack of any signs or symptoms, a single sign or symptom, an op-
portunistic disease according to the Centers for Disease Control
and Prevention (CDC) classiﬁcation stage B or C, presence of
symptoms or signs not included in Table 1, evidence of unusual
clinical manifestations of PHI as described in the literature
(Supplementary Appendix 1), or other symptoms or signs. If
patients were classiﬁed into the group of atypical ARS (eg,
Table 2. Baseline Characteristics of 290 Patients With Primary Human Immunodeﬁciency Virus Infection Presenting With Typical vs
Atypical Symptoms of Acute Retroviral Syndrome
Characteristic
Total Patients Typical ARS
Atypical ARS
Symptomatic Asymptomatic
n % or Range n % or Range n % or Range n % or Range
Number of patients 290 100 202 70 74 25 14 5
Male 271 93 191 95 68 92 12 86
Female 19 7 11 5 6 8 2 14
Age (y) 36 18–70 35 18–60 38 19–70 33 20–51
Human immunodeficiency virus type 1 Subtype Ba 220 76 163 81 47 64 10 71
Transmission mode
Men who have sex with men 225 78 161 80 52 70 12 86
Heterosexual 59 20 35 16 22 30 2 14
Intravenous drug users 4 1 4 3 0 0
Othersb 2 1 1 1 0 0
STIsc 49 17 37 18 9 12 3 21
Transmitted drug resistance 23 8 13 6 7 9 3 21
Fiebig stagesd
I–II 3 1 3 2 0 0 0 0
II–III 48 17 39 19 11 15 0 0
IV–VI 218 75 144 71 60 82 14 100
Viral load log10 RNA 6.6 1.8–8 6.6 2.3–8 6.7 2.7–8 5.1 1.8–5.9
CD4+ cell count, cells/µL 429 75–1255 424 75–1255 431 127–1040 498 326–630
Initial care setting
Primary care physician 141 49 107 53 32 43 2 14
Hospital 69 24 37 18 28 38 4 29
STI outpatient clinic 42 15 33 16 7 9 2 14
Othere 55 19 24 12 5 7 6 43
Unknown 3 1 1 1 2 3 0 000
Required hospitalization 50 17 22 11 38 43 0 0
Abbreviations: ARS, acute retroviral syndrome; STI, sexually transmitted infection.
a Other subtypes: CRF01_AE, C, A, F1, G, CRF02_AG, CRF14_BG, A1D, CR 12_BF, D.
b One case of a needle stick injury in a medical setting.
c Concomitant STIs: syphilis and/or chlamydia and/or gonorrhea and/or genital herpes.
d In 21 patients, a Fiebig stage could not be assigned due to missing p24-antigen values.
e Other than infectious disease specialist or other institutions (eg, dermatologist, gynecologist, blood donation center).
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Table 3. Atypical Clinical Presentations in 88 of 290 Patients With a Primary Human Immunodeﬁciency Virus Infection
Clinical Presentation N (%)
Acute Infection,
n (%) Mean CD4+ (%)
Mean Viral Load,
log10RNA Inpatient, n (%)
Total 88 (100) 71 (79) 460 (27) 5.1 38 (43)
Opportunistic diseasesa
Candida stomatitis/esophagitisb 13 (14) 12 (92) 346 (26) 6.7 8 (62)
CMV colitisc 1 (1) . . . 164 (22) 6.5 1 (100)
CMV gastritis 1 (1) 1 (100) 427 (26) 6.1 . . .
CMV hepatitis 2 (2) 2 (100) 432 (24) 6.7 2 (100)
Multisegmental herpes zoster 1(1) 1 (100) 305 (21) 5.4 . . .
Autoimmune thrombocytopeniad 1 (1) 1 (100) 165 (24) 6.4 1 (100)
Peripheral polyradiculoneuritis 1 (1) 1 (100) 215 (9) 6.0 . . .
Severe diarrhea >30 d 1 (1) 1 (100) 343 (28) 6.0 2 (50)
Total opportunistic diseases 21 (23) 19 (90) 299 (23) 6.2 14 (67)
Central nervous system
Severe encephalitis 2 (2) 2 (100) 480 (35) 6.5 2 (100)
Herpes simplex virus 1 meningitis 1 (1) 1 (100) 685 (35) 6.3 1 (100)
Paresis (eg, facio-brachial) 3 (3) 2 (66) 460 (16) 6.8 2 (66)
Prolonged vertigo 1 (1) 1 (100) 222 (33) 6.5 1 (100)
Acute psychiatric disorder 3 (3) 1 (33) 466 (19) 6.5 1 (33)
Distal paresthesias, aphasia 1 (1) 1 (100) 589 (18) 4.8 . . .
Total central nervous system 11 (12) 8 (73) 483 (26) 6.2 7 (64)
Eye
Herpes keratitis 1 (1) 1 (100) 470 (18) 5.6 . . .
Gastrointestinal tract
Unilateral or bilateral tonsillitis 6 (7) 4 (66) 364 (29) 6.9 3 (50)
herpes simplex virus type 1 stomatitis/esophagitis/anitis 1 (1) 1 (100) 389 (38) 6.9 1 (100)
Severe gastritis with gastricc bleeding 1 (1) 1 (100) 503 (36) 8.0 1 (100)
Diarrhea (only symptom) 1 (1) 1 (100) 602 (34) 3.4 . . .
Acalculous cholecystitisc 1 (1) 1 (100) 643 (29) 7.0 1 (100)
Appendicitis-like illnessc 1 (1) 1 (100) 840 (35) 4.2 1 (100)
Anal abscess with Enterococcus faeciume,c 1 (1) 1 (100) 277 (18) 6.2 1 (100)
Anitis 1 (1) . . . 378 (25) 6.7 . . .
Total gastrointestinal symptoms 13 (14) 10 (77) 499 (31) 6.1 8 (62)
Respiratory tract
Pneumonia 3 (3) 3 (100) 260 (15) 6.1 1 (33)
Upper respiratory tract infection 2 (2) 2 (100) 257 (25) 5.0 . . .
Total respiratory symptoms 5 (6) 5 (100) 258 (20) 5.6 1 (20)
Heart
Acute atrial fibrillation 1 (1) 1 (100) 329 (17) 6.6 . . .
Urogenital tract
Acute renal failure 2 (2) 1 (100) 355 (43) 5.0 2 (100)
Nonbacterial prostatitis 1 (1) . . . 990 (38) 3.8 . . .
Epididymitisc 1 (1) 1 (100) 196 (21) 3.7 1 (100)
Total urogenital symptoms 3 (3) 2 (66) 514 (34) 4.1 3 (66)
Skin and soft tissue
Impetigo contagiosa 1 (1) 1 (100) 432 (35) 5.4 . . .
Soft tissue infection 3 (3) 3 (100) 664 (31) 4.5 2 (100)
Hair loss 1 (1) . . . 698 (40) 4.9 . . .
Severe dermatitis 3 (3) 2 (75) 774 (26) 5.9 . . .
Total, skin/soft tissue symptoms 8 (9) 6 (75) 546 (29) 5.2 2 (25)
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manifesting with cytomegalovirus [CMV] colitis), their accom-
panying symptoms or signs (eg, fever, diarrhea) were not addi-
tionally counted as typical ARS symptoms. In patients with
atypical ARS who presented with multiple diseases, classiﬁcation
into the affected organ system was based on their primary clinical
symptom or sign and they were counted only once. If patients
presented with an opportunistic disease plus another atypical
manifestation of PHI, their case was counted as opportunistic dis-
ease and not classiﬁed within 1 of the different organ systems.
Statistical Analysis
We used logistic regression to test whether typical vs atypical ARS
was associated with the initial place of presentation (hospital vs
ambulatory healthcare institutions) and to test whether it was as-
sociated with subsequent hospitalization. Since time to diagnosis
(ie, time from the EDI to the ﬁrst positive HIV test) was not nor-
mally distributed, we used the Kruskal–Wallis test to determine
whether time to diagnosis differed among patients with different
types of presentation (ie, typical ARS, symptomatic atypical ARS,
and asymptomatic presentation). Finally, we used the Wilcoxon
rank-sum test to determine whether the time to diagnosis dif-
fered between patients who initially presented to an STI outpa-
tient clinic and patients diagnosed at other institutions.
RESULTS
Patient Characteristics
We analyzed 290 individuals with a documented PHI, including
271 (93%) males. The baseline characteristics are shown in Fig-
ure 1 and summarized in Table 2. A total of 202 (70%) patients
were classiﬁed in the group of typical ARS and 88 (30%) in the
group of atypical ARS. In the latter group, 74 (25%) presented
with atypical signs and symptoms of ARS, and 14 (5%) were
asymptomatic (Table 3). The majority of patients (49%) ﬁrst con-
sulted their primary care physician during the phase of serocon-
version (Table 2). Patients with an atypical ARS presented more
frequently to a hospital compared with patients with typical ARS
(P < .001; odds ratio [OR], 2.7; 95% conﬁdence interval [CI], 1.5,
4.5). Fifty (17%) of the 290 patients required hospitalization.
First Diagnosis During the Phase of Seroconversion
The ﬁrst established diagnoses, when patients initially presented
with symptoms or signs of PHI, are summarized in Table 4.
HIV infection was suspected during the ﬁrst medical attendance
in only 112 (38%) patients.
Atypical Presentation of Primary HIV-1 Infection
Of all 290 patients, 88 (30%) had an atypical ARS manifestation
(Table 3). Of these, 14 (16%) were completely asymptomatic and
were diagnosed by physician-initiated HIV screening or testing
requested by the patient. The remaining 74 (84%) patients pre-
sented symptomatically with a diverse pattern of symptoms
and signs (Table 3). The gastrointestinal (GI) tract and the central
nervous system (CNS) were the most frequently affected organ
systems. The opportunistic diseases and the atypical manifesta-
tions which occurred during PHI and affected different organ
systems are speciﬁed in the following list:
Opportunistic diseases
Twenty-one of 88 (24%) patients with atypical ARS presented
with an HIV-associated CDC stage B or C illness. Candida sto-
matitis and/or esophagitis were the most frequent opportunistic
diseases; 6 patients presented with CMV disease, including 2
with histologically proven colitis and gastritis and 2 with
Table 3 continued.
Clinical Presentation N (%)
Acute Infection,
n (%) Mean CD4+ (%)
Mean Viral Load,
log10RNA Inpatient, n (%)
Blood system
Severe pancytopeniaf 3 (3) 3 (100) 329 (29) 6.7 3 (100)
Thrombophlebitis Vena brachiocephalica 1 (1) 1 (100) 127 (12) 5.8 . . .
Total hematologic findings 5 (6) 5 (100) 338 (20) 5.6 3 (80)
Constitutional symptoms
Weight loss or night sweats 7 (8) 7 (100) 476 (26) 5.2 . . .
Symptomatic atypical PHI 74 (85) 64 (71) 421 (24) 5.0 38 (43)
Asymptomatic atypical PHI 14 (15) 7 (8) 499 (30) 4.4 . . .
Abbreviations: CMV, cytomegalovirus; PHI, primary human immunodeficiency virus infection.
a According to the Centers for Disease Control and Prevention classification state B or C.
b In 2 cases, together with severe neurological symptoms.
c Surgical intervention required (eg, laparotomy, laparoscopy, rectostomy).
d Together with generalized herpes simplex 1 skin infection.
e Leading to rectostomy; in addition, bilateral Pseudomonas aeruginosa pneumonia, arthritis of the left knee, acute renal insufficiency.
f In 1 case, together with Enterococcus faecalis bacteremia, pneumonia, skin abscesses, retinal hemorrhagia.
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hepatitis and documented CMV seroconversion and viremia.
Other opportunistic diseases included multidermal herpes zos-
ter, HIV-associated autoimmune thrombocytopenia, peripheral
demyelinating polyradiculoneuritis, and diarrhea for several
weeks with wasting syndrome.
Central nervous system
The most severe CNSmanifestations included 2 cases with fulmi-
nant encephalitis, leading to a stay in the intensive care unit for 1
patient. Other CNS manifestations were facial and occulomotor
nerve palsy; prolonged vertigo, leading to an otorhinolaryngology
assessment (in the absence of syphilis); acute psychiatric disor-
ders (eg, psychosis, severe depression); and herpes simplex
virus type 1 (HSV-1) meningitis.
Ocular
One patient presented with HSV-1 keratitis of the right eye dur-
ing PHI.
GI tract
Unilateral or bilateral tonsillitis, in the absence of other STIs,
was present in 6 patients. In all of these patients, the ﬁrst sus-
pected diagnosis was a group A streptococcal tonsillitis, and an-
tibiotics were prescribed. Severe morbidity in other patients was
due to necrotizing esophagitis, HSV-1 panmucositis, gastric
ulcer that caused anemic bleeding and required surgical inter-
vention, acalculous cholecystitis, and an anal abscess due to
Enterococcus faecium. The patient with anal abscess was a pre-
viously healthy 28-year-old man who has sex with men (MSM)
and presented with concomitant Pseudomonas aeruginosa sep-
sis, bilateral pneumonia, septic knee arthritis, and Candida
esophagitis. He required several surgical interventions and a de-
scendostomy for 3 months. One patient presented with an ap-
pendicitis-like illness that resulted in explorative laparotomy.
Respiratory tract
In 3 patients, pneumonia (viral) was the main clinical ﬁnding
during PHI, without evidence of a bacterial etiology. Two of
these patients were hospitalized due to severe respiratory
distress.
Heart
A 45-year-old man reported new onset of chest pain and dysp-
nea. The electrocardiogram at the time of admission showed a
new-onset atrial ﬁbrillation, perhaps triggered by the acute HIV
infection. Further investigations revealed no underlying cardiac
diseases (eg, coronary heart disease, arterial hypertension).
Urogenital tract
Manifestations included 2 patients with acute renal failure,
probably caused by a toxic effect of HIV that led to tubulopathy,
a prerenal component, and concomitant intake of nonsteroidal
antiinﬂammatory drugs. One patient presented with acute
Figure 1. Classiﬁcation of 290 patients with primary human immunodeﬁciency virus infection according to their infection and acute retroviral syndrome
(ARS) state. Abbreviation: HIV-1, human immunodeﬁciency virus type 1.
Table 4. Initial Diagnosis of First Attended Healthcare Provider
or Reason for Human Immunodeﬁciency Virus (HIV) Test at Time
Point of HIV Seroconversion
Suspected Diagnosis Frequency (%)
Acute retroviral syndrome 112 (38)
Viral infection other than HIV (eg, mononucleosis
infectiosa)
49 (17)
Routine HIV test 35 (12)
Bacterial infection (eg, Streptococcal pharyngitis) 16 (6)
Gastroenteritis 11 (4)
Sexually transmitted infection (eg, syphilis) 10 (3)
Othera 55 (19)
Abbreviation: HIV, human immunodeficiency virus.
a Includes a variety of diseases (eg, infective endocarditis, diverticulitis,
appendicitis, malignant lymphoma, Lyme disease). No data were available for
2 patients.
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epididymitis requiring surgical intervention, and 1 presented
with acute prostatitis.
Skin and soft tissue
Eight patients reported new-onset skin and soft tissue manifes-
tations as primary clinical signs during PHI. One patient expe-
rienced severe acute hair loss.
Hematologic system
A 63-year-old man presented with pancytopenia, Enterococcus
faecalis septicemia, abscess of the right hand, and retinal bleed-
ing. One patient suffered from acute Mondor disease (ie, throm-
bophlebitis of the superﬁcial veins of the breast and anterior
chest wall), which resolved after starting early ART.
Constitutional symptoms
Seven patients reported either weight loss or night sweats dur-
ing the time of seroconversion.
Course of Atypical PHI and Outcome
Patients with atypical ARS (n = 88) were hospitalized 4 times
more often compared with patients with typical ARS (n = 202;
43% vs 11%; P < .001; OR, 4.4; 95% CI, 2.4, 8.3). There was no
PHI-associated death in our cohort. An invasive diagnostic or
therapeutic procedure was required in 6 (6.5%) of the 88 pa-
tients with atypical ARS. One patient underwent hemicolec-
tomy following colonic perforation associated with CMV
enteritis, 1 patient with anemic gastric bleeding required urgent
gastroscopy with clipping, 2 patients who presented with acute
abdominal pain during seroconversion underwent explorative
laparotomy, 1 patient with anal abscess required a transient
ileostomy, and 1 patient with epididymitis underwent a surgical
epididymectomy.
Time to Diagnosis in Patients With Atypical Primary HIV-1
Infection
We determined the time interval between the EDI and the ﬁrst
positive HIV test in patients with typical ARS, atypical sympto-
matic ARS, and asymptomatic PHI. We found that atypical pre-
sentation did not lead to a signiﬁcant delay in diagnosis.
Median time to ﬁrst positive test among asymptomatic newly
infected persons was 42 days (95% bootstrap conﬁdence inter-
val, 18.4, 65.6); among patients with atypical symptomatic ARS,
32 days (25.8, 38.2); and among patients with typical ARS, 29
days (24.8, 33.2; Kruskal–Wallis test for differences between
groups, P = .3). Patients who initially presented to an STI outpa-
tient clinic were diagnosed signiﬁcantly earlier compared with
patients admitted to a hospital or primary care physician. Median
time to ﬁrst positive test among patients attending an STI outpa-
tient clinic was 21 days (95% bootstrap conﬁdence interval, 18,
31); among patients presenting to a hospital, 30 days (20, 61);
and among patients presenting to their primary care physician,
33 days (22, 53; Wilcoxon rank-sum test for differences between
STI outpatient clinic and other groups, P < .0002).
DISCUSSION
In this prospective, single-center, cohort study that included
290 patients with a well-documented PHI, we found that one
third of patients presented with atypical clinical manifestation
during HIV seroconversion. Almost half of patients with atyp-
ical presentation (43%) were severely ill and required inpatient
treatment, which also had a potential economic impact. Only in
112 (38%) patients was acute HIV infection suspected by phy-
sicians at the ﬁrst visit. Surprisingly, clinical presentation with
atypical ARS did not signiﬁcantly delay PHI diagnosis.
The proportion and clinical spectrum of unusual clinical pre-
sentations of PHI have not prospectively and systematically
been studied and published in the literature, and there is no
consensus when clinical manifestations of PHI are considered
atypical. We therefore classiﬁed typical and atypical PHI
based on published data that we then compared with the results
of the present work. An unexpectedly large number of patients
(30%) fulﬁlled the criteria for atypical PHI. To date, more than
30 cases describing atypical clinical manifestations during PHI
have been published, including a broad spectrum of diseases
and affected organ systems (Supplementary Appendix 1). Our
review of the literature showed that, similar to our study,
most of the anecdotal atypical cases affected the GI tract or
the CNS (Supplementary Appendix 1). An unfavorable out-
come is reported in approximately half of the atypical PHI
cases. The high prevalence of GI tract involvement in our cohort
may partially be explained by the route of HIV transmission—
the majority of our patients (78%) are MSM. Studies in humans
and animals have shown that after rectogenital infection, HIV
preferentially infects resting CD4+ cells from the gut-associated
lymphoid tissue, leading to a massive cytokine-mediated local
inﬂammation [19]. This mechanism may result in either direct
cytotoxic-related tissue damage (eg, HIV-associated colitis) or
local reactivation of other viral infections (eg, CMV colitis).
Furthermore, a recent publication reported that HIV invades
the CNS as early as 8 days after transmission, causing intrathe-
cal immune activation and inﬂammation, which led to clinical
manifestations in a substantial number of patients [20].
We did not ﬁnd that atypical manifestations delayed HIV di-
agnosis signiﬁcantly, although patients with typical ARS were
diagnosed a few days earlier than those with atypical PHI.
This ﬁnding may be explained by the often severe clinical pre-
sentation of patients, which possibly led them to associate their
HIV transmission risk with the subsequent illness and to re-
quest testing; the large proportion of MSM who possibly re-
quested early testing; awareness of past risk behavior, which
also led asymptomatic persons to request testing; and the high
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variability of the recognition of typical ARS, which may have
diminished or eliminated the power to detect a deleterious effect
of atypical ARS, in part, due to the relatively small number of
total events as well as atypical presentations.
Although clinical manifestations of ARS have repeatedly
been described, PHI is still often missed. A recent review
on the utility of clinical evaluation to detect PHI concluded
that the assessment of symptoms and signs might be unreli-
able for diagnosis [21]. In our cohort, PHI was initially sus-
pected in only 112 of the 290 patients (38%) by primary care
physicians or at hospital emergency units. Healthcare provid-
ers and patients should be aware of the substantial proportion
of unusual manifestations of acute HIV infection. However,
physicians should search for other underlying diseases in
cases where signs and symptoms may be not clearly attribut-
able to HIV itself so as to not miss diseases that require spe-
ciﬁc treatment.
Although the majority of our patients (94%) presented symp-
tomatically during PHI, we assume that this number is biased
for many reasons. First, asymptomatic younger persons usually
do not routinely attend healthcare institutions, and HIV infec-
tion therefore will only be detected if sexually active persons are
aware of their risks and request testing. Second, our cohort did
not prospectively include and observe an HIV-negative control
group. In a prospective observational study that included indi-
viduals in East Africa and Thailand at high risk for HIV infec-
tion, O’Connell and colleagues reported that more than 50%
of all participants enrolled into the study presented asymptom-
atically at the time point of seroconversion [22]. Thus, it is
possible that the proportion of patients with atypical (ie, asymp-
tomatic) ARS was considerably underestimated in our study.
However, published data on ARS symptoms from studies that
included an HIV-negative control group are potentially limited
due to an inherent recall bias (ie, patients do not remember
transient or preceding nonspeciﬁc symptoms in the previous
6 months and, furthermore, would probably not be enrolled
in a study if they had no risk at all). Third, common symptoms
or signs of PHI also occur in many other clinical situations
apart from PHI, for example, other viral infections, and may
be misinterpreted. Symptoms observed among HIV-negative
“control” persons in prospective HIV seroconverter studies
are frequent and include fever or pharyngitis due to etiologies
other than HIV in up to 20% or a preceding acute illness in
up to 40% in the previous 6 months [3–6, 10].
The strengths of our study are the prospective design, the
large number of observed seroconverters, the systematic docu-
mentation by a stable and experienced study team, and the strict
use of clinical and laboratory criteria to deﬁne PHI. However,
limitations include that the deﬁnition used to classify atypical
PHI is not formally validated. Since there was no broadly
used deﬁnition of ARS, we had to propose de novo criteria,
which we based on an extensive literature search. However, a
coincidental comorbidity during PHI cannot be ruled out in
some cases. One additional limitation is the lack of information
of howmany of the HIV tests were ordered by the physicians for
suspected HIV infection with respective to how many tests were
requested by the patients themselves. This information would
be helpful to determine whether it would be more effective in
terms of early diagnosis to inform physicians on potential
symptoms and signs of PHI or whether the focus should be
on advocating testing in populations at risk. Last, our cohort in-
cluded only 1 case infected by intravenous drug use, whereas
99% were infected by sexual routes. Some studies reported a
lower frequency of ARS symptoms among intravenous drug
users. However, whether this is a true ﬁnding or whether PHI
symptoms were observed less frequently because of other sub-
stantial comorbidities in intravenous drug users remains
unknown [7].
In conclusion, unexpected atypical presentations and op-
portunistic diseases occur in a substantial proportion of
patients with PHI, often causing severe disease. Our ﬁndings
warrant general HIV testing in populations at risk.
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